[시장보고서]북미의 내피기능장애 시장 : 지역별 분석 - 원인별, 검사 유형별, 최종 사용자별, 예측(-2028년)

북미의 내피기능장애 시장 : 지역별 분석 - 원인별, 검사 유형별, 최종 사용자별, 예측(-2028년)

North America Endothelial Dysfunction Market Forecast to 2028 - Regional Analysis - by Cause, Test Type, and End User

상품코드 : 1420203 해당 상품은 즉시 배송 가능합니다

리서치사 : The Insight Partners

발행일 : 2023년 12월

페이지 정보 : 영문 115 Pages

라이선스 & 가격 (부가세 별도)

US $ 3,450

￦ 4,793,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 4,450

￦ 6,182,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,450

￦ 7,571,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

북미의 내피기능장애 시장 규모는 2022년 9억 5,183만 달러에 달할 것으로 예상되며, 2022-2028년 연평균 4.6% 성장하여 2028년에는 12억 4,730만 달러에 달할 것으로 전망됩니다.

심혈관 질환 증가로 북미 내피 기능 부전 시장 성장 촉진

세계보건기구(WHO)에 따르면 심혈관 질환(CVD)은 전 세계 주요 사망 원인 중 하나이며, 매년 3,000만 명이 뇌졸중을 경험하고 있으며, CVD에는 뇌혈관 질환, 관상동맥 질환, 류마티스성 심장 질환, 관상동맥 질환(CAD) 등이 포함됩니다. 중 가장 흔한 질환으로 관상동맥 내피하강에 지질과 면역세포의 축적, 즉 죽상동맥경화증을 특징으로 합니다. 혈관 내피의 염증 반응이 관여하며, CAD는 죽상동맥경화로 인한 관상동맥 내강의 협착, 경련, 폐색으로 인한 심근의 허혈, 저산소증, 괴사가 특징입니다. 전 세계적으로 사망 원인 1위로 꼽힙니다. 미국 질병예방통제센터(CDC)에 따르면, 미국에서는 6,000만 명 이상의 여성(44%)이 심장질환을 앓고 있습니다. 심장병은 미국 여성의 사망 원인 중 1위이며, 연령에 관계없이 발병할 수 있으며, 2021년에는 31만661명의 여성 사망자, 즉 여성 사망자 5명 중 1명이 심장병으로 사망했습니다.

미국심장협회에 따르면, 미국 성인의 거의 절반이 심혈관 질환을 앓고 있으며, 2035년까지 미국 인구의 45.1%에 해당하는 1억 3천만 명 이상이 심혈관 질환을 앓을 것으로 예상하고 있습니다. 따라서 내피기능장애로 인한 심혈관 질환의 높은 유병률이 시장을 주도하고 있습니다.

북미의 내피기능장애 시장 개요

북미의 내피기능장애 시장은 미국, 캐나다, 멕시코의 주요 3개국을 기준으로 분석됩니다. 이 지역 시장 확대는 심장병 유병률 증가와 심장병학 인포매틱스에 대한 투자 증가에 기인합니다. 미국은 CAD 부담 증가, 잘 구축된 의료 인프라, 첨단 내피 기능 부전 치료제 및 장치 개발을 위한 R&D 활동 등의 요인으로 북미 내피 기능 부전 시장에서 가장 큰 규모를 차지하고 있습니다.

북미의 내피기능장애 시장 매출 및 2028년까지의 예측(금액)

북미 내피 기능 부전 시장 세분화

북미의 내피기능장애 시장은 원인, 검사 유형, 최종 사용자 및 국가별로 분류됩니다.

원인별로 북미의 내피기능장애 시장은 고혈압, 고콜레스테롤혈증, 비만, 당뇨병, 베체트병, 기타로 구분되며, 2022년 북미의 내피기능장애 시장 점유율은 고혈압 부문이 가장 큰 비중을 차지했습니다.

검사 유형에 따라 북미의 내피기능장애 시장은 침습적 검사와 비침습적 검사로 구분됩니다. 침습적 검사 부문은 2022년 북미의 내피기능장애 시장 점유율을 크게 유지했습니다. 비침습적 검사 부문은 유동 매개 확장, 말초동맥 토노메트리(PAT), 정맥 폐색 전산화 단층 촬영, 순환 마커 및 기타로 세분화됩니다.

최종 사용자별로 북미의 내피기능장애 시장은 병원, 진단센터, 클리닉 및 기타로 분류되며, 2022년 북미의 내피기능장애 시장 점유율은 병원 부문이 가장 큰 비중을 차지했습니다.

국가별로 보면 북미의 내피기능장애 시장은 미국, 캐나다, 멕시코로 구분됩니다. 미국은 2022년 북미의 내피기능장애 시장을 장악했습니다.

ZOLL Medical Corp, Lawrence Berkeley National Laboratory, Endothelix Inc, Perimed AB, SMART Medical Ltd, Everist Health Inc, Medizinische Messtechnik GmbH 등이 이 지역의 내피기능장애 시장에서 사업을 전개하고 있는 주요 기업들입니다.

영문목차

The North America endothelial dysfunction market is expected to grow from US$ 951.83 million in 2022 to US$ 1,247.30 million by 2028. It is estimated to grow at a CAGR of 4.6% from 2022 to 2028.

Increasing Incidences of Cardiovascular Diseases Fuels North America Endothelial Dysfunction Market

According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are among the leading causes of death worldwide, and ~30 million people experience a stroke each year. CVDs include cerebrovascular disease, coronary heart disease, rheumatic heart disease, and coronary artery disease (CAD). CAD is the most common disease among all cardiovascular diseases, and it is characterized by the accumulation of lipids and immune cells in the subendothelial space of the coronary arteries or atherosclerosis. It involves the inflammatory response of the vascular endothelium. CAD is characterized by ischemia, hypoxia, or necrosis of the myocardium resulting from narrowing, spasm, or obstruction of the coronary artery lumen by atherosclerosis. It has become the leading cause of death worldwide. According to the Centers for Disease Control and Prevention (CDC), over 60 million women (44%) in the US suffer from some form of heart disease. Heart disease is the leading cause of death among women in the US and can affect women of any age. In 2021, it caused 310,661 deaths among women, i.e., nearly one in five female deaths.

According to the American Heart Association, almost half of all adults in the US suffer from a type of CVD. Over 130 million people, i.e., 45.1% of the US population, are projected to suffer from a type of CVD by 2035. Therefore, the high prevalence of cardiovascular diseases due to endothelial dysfunction drives the market.

North America Endothelial Dysfunction Market Overview

The North American endothelial dysfunction market is analyzed on the basis of three major countries: the US, Canada, and Mexico. The market expansion in the region can be attributed to an increase in the incidence of cardiac diseases and rising investments in cardiology informatics. The US holds the largest size of the endothelial dysfunction market in North America owing to factors such as the increasing burden of CAD, established healthcare infrastructure, and R&D activities undertaken to develop advanced endothelial dysfunction drugs and devices.

North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)

North America Endothelial Dysfunction Market Segmentation

The North America endothelial dysfunction market is segmented into cause, test type, end user, and country.

Based on cause, the North America endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, behcet's disease, and others. The hypertension segment registered the largest North America endothelial dysfunction market share in 2022.

Based on test type, the North America endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held a larger North America endothelial dysfunction market share in 2022. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.

Based on end user, the North America endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held the largest North America endothelial dysfunction market share in 2022.

Based on country, the North America endothelial dysfunction market is segmented into the US, Canada, and Mexico. The US dominated the North America endothelial dysfunction market in 2022.

ZOLL Medical Corp, Lawrence Berkeley National Laboratory, Endothelix Inc, Perimed AB, SMART Medical Ltd, Everist Health Inc, and Medizinische Messtechnik GmbH are some of the leading companies operating in the endothelial dysfunction market in the region.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America endothelial dysfunction market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America endothelial dysfunction market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the endothelial dysfunction market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 North America Endothelial Dysfunction Market - by Cause
- 1.3.2 North America Endothelial Dysfunction Market - by Test Type
- 1.3.3 North America Endothelial Dysfunction Market - by End User
- 1.3.4 North America Endothelial Dysfunction Market - by Country

2. North America Endothelial Dysfunction Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Endothelial Dysfunction Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America PEST Analysis
4.3 Expert Opinion

5. North America Endothelial Dysfunction Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increasing Incidences of Cardiovascular Diseases
- 5.1.2 Rising Incidences of High Cholesterol, Diabetes And Obesity
5.2 Market Restraints
- 5.2.1 Disadvantages Associated with the Techniques for Screening of Endothelial Dysfunction
5.3 Market Opportunities
- 5.3.1 Rising Usage of Novel Biomarkers and Therapeutic Strategies
5.4 Future Trends
- 5.4.1 Use of Noninvasive Methods to Assess Endothelial Dysfunction
5.5 Impact Analysis

6. Endothelial Dysfunction Market - North America Analysis

6.1 North America Endothelial Dysfunction Market Revenue Forecast and Analysis

7. North America Endothelial Dysfunction Market Analysis - by Cause

7.1 Overview
7.2 North America Endothelial Dysfunction Market, By Cause, 2022 & 2028 (%)
7.3 Hypertension
- 7.3.1 Overview
- 7.3.2 Hypertension: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.4 Diabetes
- 7.4.1 Overview
- 7.4.2 Diabetes: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.5 Hypercholestrolaemia
- 7.5.1 Overview
- 7.5.2 Hypercholestrolaemia: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.6 Behcet's Disease
- 7.6.1 Overview
- 7.6.2 Behcet's Disease: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.7 Obesity
- 7.7.1 Overview
- 7.7.2 Obesity: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.8 Others
- 7.8.1 Overview
- 7.8.2 Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)

8. North America Endothelial Dysfunction Market Analysis - by Test Type

8.1 Overview
8.2 North America Endothelial Dysfunction Market, By Test Type, 2022 & 2028 (%)
8.3 Invasive Tests
- 8.3.1 Overview
- 8.3.2 Invasive Tests: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4 Non-Invasive Tests
- 8.4.1 Overview
- 8.4.2 Non-Invasive Tests: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
- 8.4.3 Flow Mediated Dilatory
  - 8.4.3.1 Overview
  - 8.4.3.2 Flow Mediated Dilatory: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
- 8.4.4 Venous Occlusion Plethysmography
  - 8.4.4.1 Overview
  - 8.4.4.2 Venous Occlusion Plethysmography: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
- 8.4.5 Peripheral Arterial Tonometry (PAT)
  - 8.4.5.1 Overview
  - 8.4.5.2 Peripheral Arterial Tonometry (PAT): North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
- 8.4.6 Circulating Markers
  - 8.4.6.1 Overview
  - 8.4.6.2 Circulating Markers: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
- 8.4.7 Others
  - 8.4.7.1 Overview
  - 8.4.7.2 Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)

9. North America Endothelial Dysfunction Market Analysis - by End User

9.1 Overview
9.2 North America Endothelial Dysfunction Market, By End User, 2022 & 2028 (%)
9.3 Hospitals
- 9.3.1 Overview
- 9.3.2 Hospitals: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9.4 Diagnostics Centers
- 9.4.1 Overview
- 9.4.2 Diagnostics Centers: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9.5 Clinics
- 9.5.1 Overview
- 9.5.2 Clinics: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)

10. North America Endothelial Dysfunction Market - Revenue and Forecast to 2028 - Country Analysis

10.1 North America: Endothelial Dysfunction Market
- 10.1.1 Overview
  - 10.1.1.1 US: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.1.1 Overview
    - 10.1.1.1.2 US: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.1.3 US: Endothelial Dysfunction Market, by Cause, 2020-2028 (US$ Million)
    - 10.1.1.1.4 US: Endothelial Dysfunction Market, by Test Type - 2020-2028 (US$ Million)
    - 10.1.1.1.4.1 US: Endothelial Dysfunction Market, by Non-Invasive Tests - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.1.5 US: Endothelial Dysfunction Market, by End User 2020-2028 (US$ Million)
  - 10.1.1.2 Canada: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.2.1 Overview
    - 10.1.1.2.2 Canada: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.2.3 Canada: Endothelial Dysfunction Market, by Cause, 2020-2028 (US$ Million)
    - 10.1.1.2.4 Canada: Endothelial Dysfunction Market, by Test Type - 2020-2028 (US$ Million)
    - 10.1.1.2.4.1 Canada: Endothelial Dysfunction Market, by Non-Invasive Tests - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.2.5 Canada: Endothelial Dysfunction Market, by End User 2020-2028 (US$ Million)
  - 10.1.1.3 Mexico: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.3.1 Overview
    - 10.1.1.3.2 Mexico: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
    - 10.1.1.3.3 Mexico: Endothelial Dysfunction Market, by Cause, 2020-2028 (US$ Million)
    - 10.1.1.3.4 Mexico: Endothelial Dysfunction Market, by Test Type - 2020-2028 (US$ Million)
    - 10.1.1.3.4.1 Mexico: Endothelial Dysfunction Market, by Non-Invasive Tests - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.3.5 Mexico: Endothelial Dysfunction Market, by End User 2020-2028 (US$ Million)

11. North America Endothelial Dysfunction Market-Industry Landscape

11.1 Overview
11.2 Growth Strategies in the Endothelial Dysfunction Market
11.3 Inorganic Growth Strategies
- 11.3.1 Overview
11.4 Organic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 ZOLL Medical Corp
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Lawrence Berkeley National Laboratory
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Endothelix Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Perimed AB
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6
- 12.4.7 Key Developments
12.5 SMART Medical Ltd
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Everist Health Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Medizinische Messtechnik GmbH
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms

한글목차

목차

제1장 서론

제2장 북미의 내피기능장애 시장 - 중요 요점

제3장 조사 방법

제4장 북미의 내피기능장애 시장 - 시장 구도

제5장 북미의 내피기능장애 시장 - 주요 시장 역학

제6장 내피기능장애 시장 : 북미 분석

제7장 북미의 내피기능장애 시장 분석 : 원인별

제8장 북미의 내피기능장애 시장 분석 : 검사 유형별

제9장 북미의 내피기능장애 시장 분석 : 최종사용자별

제10장 북미의 내피기능장애 시장 - 매출과 예측(-2028년) : 국가별 분석

제11장 북미의 내피기능장애 시장 - 업계 상황

제12장 기업 개요

제13장 부록